In Silico Fragment-Based Design Identifies Subfamily B1 Metallo-β-lactamase Inhibitors

Journal of Medicinal Chemistry

Volumn 61, Issue 3, 2018, Pages 1255-1260

  Cain, Ricky ^a   Brem, Jürgen ^b   Zollman, David ^b   McDonough, Michael A ^b   Johnson, Rachel M ^a   Spencer, James ^c   Makena, Anne ^b   Abboud, Martine I ^b   Cahill, Samuel ^b   Lee, Sook Y ^b,d   McHugh, Peter J ^d   Schofield, Christopher J ^b   Fishwick, Colin W G ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYL 2 SULFONYLMETHYLBENZOIC ACID; ANTIINFECTIVE AGENT; BETA LACTAMASE; D SERINE BETA LACTAMASE; HYDROLASE INHIBITOR; MEROPENEM; METALLO BETA LACTAMASE; METALLO BETA LACTAMASE INHIBITOR; NUCLEASE; THIOL; UNCLASSIFIED DRUG; BETA LACTAMASE INHIBITOR;

ANTIBACTERIAL ACTIVITY; ARTICLE; COMPUTER MODEL; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG DESIGN; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SYNTHESIS; ENTEROBACTERIACEAE; ENZYME ACTIVE SITE; ENZYME INHIBITION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STRUCTURE ACTIVITY RELATION; CHEMISTRY; COMPUTER SIMULATION; METABOLISM; MOLECULAR MODEL; PRECLINICAL STUDY; PROTEIN CONFORMATION;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; COMPUTER SIMULATION; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; MODELS, MOLECULAR; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85042121524     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.7b01728     Document Type: Article

References (32)

1. Hamad, B. The antibiotics market. Nat. Rev. Drug Discovery 2010, 9, 675-676.
2. Molstad, S.; Lundborg, C. S.; Karlsson, A. K.; Cars, O. Antibiotic prescription rates vary markedly between 13 European countries. Scand. J. Infect. Dis. 2002, 34, 366-371.
3. Ambler, R. P. The structure of β-lactamases. Philos. Trans. R. Soc., B 1980, 289, 321-331.
4. Arulanantham, H.; Kershaw, N. J.; Hewitson, K. S.; Hughes, C. E.; Thirkettle, J. E.; Schofield, C. J. ORF17 from the clavulanic acid biosynthesis gene cluster catalyzes the ATP-dependent formation of N-glycyl-clavaminic acid. J. Biol. Chem. 2006, 281, 279-287.
5. Yang, Y.; Rasmussen, B. A.; Shlaes, D. M.; Class, A. β-lactamasesenzyme- inhibitor interactions and resistance. Pharmacol. Ther. 1999, 83, 141-151.
6. Li, H.; Estabrook, M.; Jacoby, G. A.; Nichols, W. W.; Testa, R. T.; Bush, K. In vitro susceptibility of characterized β-lactamase-producing strains tested with avibactam combinations. Antimicrob. Agents Chemother. 2015, 59, 1789-1793.
7. Stone, G. G.; Bradford, P. A.; Newell, P.; Wardman, A. In vitro activity of ceftazidime-avibactam against isolates in a phase 3 openlabel clinical trial for complicated intra-abdominal and urinary tract infections caused by ceftazidime-nonsusceptible gram-negative pathogens. Antimicrob. Agents Chemother. 2017, 61, e01820-16.
8. Faridoon, U. I.; Islam, N. An update on the status of potent inhibitors of metallo-β-lactamases. Sci. Pharm. 2013, 81, 309-327.
9. Cahill, S. T.; Cain, R.; Wang, D. Y.; Lohans, C. T.; Wareham, D. W.; Oswin, H. P.; Mohammed, J.; Spencer, J.; Fishwick, C. W.; McDonough, M. A.; Schofield, C. J.; Brem, J. Cyclic boronates inhibit all classes of β-lactamases. Antimicrob. Agents Chemother. 2017, 61, e02260-16.
10. Brem, J.; van Berkel, S. S.; Zollman, D.; Lee, S. Y.; Gileadi, O.; McHugh, P. J.; Walsh, T. R.; McDonough, M. A.; Schofield, C. J. Structural basis of metallo-β-lactamase inhibition by captopril stereoisomers. Antimicrob. Agents Chemother. 2016, 60, 142-150.
11. Brem, J.; van Berkel, S. S.; Aik, W.; Rydzik, A. M.; Avison, M. B.; Pettinati, I.; Umland, K. D.; Kawamura, A.; Spencer, J.; Claridge, T. D.; McDonough, M. A.; Schofield, C. J. Rhodanine hydrolysis leads to potent thioenolate mediated metallo-β-lactamase inhibition. Nat. Chem. 2014, 6, 1084-1090.
12. Cornaglia, G.; Giamarellou, H.; Rossolini, G. M. Metallo-β- lactamases: a last frontier for β-lactams? Lancet Infect. Dis. 2011, 11, 381-393.
13. Bebrone, C.; Delbruck, H.; Kupper, M. B.; Schlomer, P.; Willmann, C.; Frere, J. M.; Fischer, R.; Galleni, M.; Hoffmann, K. M. The structure of the dizinc subclass B2 metallo-β-lactamase CphA reveals that the second inhibitory zinc ion binds in the histidine site. Antimicrob. Agents Chemother. 2009, 53, 4464-4471.
14. Zhang, H.; Hao, Q. Crystal structure of NDM-1 reveals a common β-lactam hydrolysis mechanism. FASEB J. 2011, 25, 2574- 2582.
15. Gillet, V.; Johnson, A. P.; Mata, P.; Sike, S.; Williams, P. SPROUT: a program for structure generation. J. Comput.-Aided Mol. Des. 1993, 7, 127-153.
16. Gillet, V. J.; Newell, W.; Mata, P.; Myatt, G.; Sike, S.; Zsoldos, Z.; Johnson, A. P. SPROUT: recent developments in the de novo design of molecules. J. Chem. Inf. Model. 1994, 34, 207-217.
17. Demetriades, M.; Leung, I. K.; Chowdhury, R.; Chan, M. C.; McDonough, M. A.; Yeoh, K. K.; Tian, Y. M.; Claridge, T. D.; Ratcliffe, P. J.; Woon, E. C.; Schofield, C. J. Dynamic combinatorial chemistry employing boronic acids/boronate esters leads to potent oxygenase inhibitors. Angew. Chem., Int. Ed. 2012, 51, 6672-6675.
18. Brem, J.; Cain, R.; Cahill, S.; McDonough, M. A.; Clifton, I. J.; Jimenez-Castellanos, J. C.; Avison, M. B.; Spencer, J.; Fishwick, C. W.; Schofield, C. J. Structural basis of metallo-β-lactamase, serine-β- lactamase and penicillin-binding protein inhibition by cyclic boronates. Nat. Commun. 2016, 7, 12406.
19. Miyaura, N.; Yamada, K.; Suzuki, A. A new stereospecific crosscoupling by the palladium-catalyzed reaction of 1-alkenylboranes with 1-alkenyl or 1-alkynyl halides. Tetrahedron Lett. 1979, 20, 3437-3440.
20. van Berkel, S. S.; Brem, J.; Rydzik, A. M.; Salimraj, R.; Cain, R.; Verma, A.; Owens, R. J.; Fishwick, C. W.; Spencer, J.; Schofield, C. J. Assay platform for clinically relevant metallo-β-lactamases. J. Med. Chem. 2013, 56, 6945-6953.
21. Irwin, J. J.; Duan, D.; Torosyan, H.; Doak, A. K.; Ziebart, K. T.; Sterling, T.; Tumanian, G.; Shoichet, B. K. An aggregation advisor for ligand discovery. J. Med. Chem. 2015, 58, 7076-7087.
22. Shoichet, B. K. Interpreting steep dose-response curves in early inhibitor discovery. J. Med. Chem. 2006, 49, 7274-7277.
23. Feng, B. Y.; Simeonov, A.; Jadhav, A.; Babaoglu, K.; Inglese, J.; Shoichet, B. K.; Austin, C. P. A high-throughput screen for aggregation-based inhibition in a large compound library. J. Med. Chem. 2007, 50, 2385-2390.
24. Brem, J.; Struwe, W. B.; Rydzik, A. M.; Tarhonskaya, H.; Pfeffer, I.; Flashman, E.; van Berkel, S. S.; Spencer, J.; Claridge, T. D.; McDonough, M. A.; Benesch, J. L.; Schofield, C. J. Studying the activesite loop movement of the Sao Paolo metallo-β-lactamase-1. Chem. Sci. 2015, 6, 956-963.
25. Mashalidis, E. H.; Sledz, P.; Lang, S.; Abell, C. A three-stage biophysical screening cascade for fragment-based drug discovery. Nat. Protoc. 2013, 8, 2309-2324.
26. Gee, C. T.; Arntson, K. E.; Urick, A. K.; Mishra, N. K.; Hawk, L. M.; Wisniewski, A. J.; Pomerantz, W. C. Protein-observed 19F-NMR for fragment screening, affinity quantification and druggability assessment. Nat. Protoc. 2016, 11, 1414-1427.
27. Lund, B. A.; Christopeit, T.; Guttormsen, Y.; Bayer, A.; Leiros, H. K. Screening and design of inhibitor scaffolds for the antibiotic resistance oxacillinase-48 (OXA-48) through surface plasmon resonance screening. J. Med. Chem. 2016, 59, 5542-5554.
28. Pettinati, I.; Brem, J.; McDonough, M. A.; Schofield, C. J. Crystal structure of human persulfide dioxygenase: structural basis of ethylmalonic encephalopathy. Hum. Mol. Genet. 2015, 24, 2458-2469.
29. Khan, A. U.; Maryam, L.; Zarrilli, R. Structure, genetics and worldwide spread of New Delhi metallo-β-lactamase (NDM): a threat to public health. BMC Microbiol. 2017, 17, 101.
30. McGeary, R. P.; Tan, D. T.; Schenk, G. Progress toward inhibitors of metallo-β-lactamases. Future Med. Chem. 2017, 9, 673- 691.
31. Li, G. B.; Abboud, M. I.; Brem, J.; Someya, H.; Lohans, C. T.; Yang, S. Y.; Spencer, J.; Wareham, D. W.; McDonough, M. A.; Schofield, C. J. NMR-filtered virtual screening leads to non-metal chelating metallo-β-lactamase inhibitors. Chem. Sci. 2017, 8, 928-937.
32. Cossar, B. C.; Fournier, J. O.; Fields, D. L.; Reynolds, D. D. Preparation of Thiols. J. Org. Chem. 1962, 27, 93-95.